You are here: Industry Insights > Fate Therapeutics

News List

Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy firstwordpharma
August 03, 2021
Fate Therapeutics , inc. announced today that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies.
Fate Announces IND Application Clearance for CRISPR-edited, iPSC-derived Cell Therapy americanpharmaceuticalreview
May 26, 2020
Fate Therapeutics announced the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for FT538, the first CRISPR-edited, iPSC-derived cell therapy.
Fate Therapeutics Announces Cancer Immunotherapies Collaboration americanpharmaceuticalreview
April 09, 2020
Fate Therapeutics announced a global collaboration and option agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH fiercebiotech
January 03, 2019
Shares of cell therapy developer Fate Therapeutics shot up more than 8% Friday morning to $15.31 after the company announced that the FDA accepted its IND application for a ......